| Literature DB >> 19910499 |
Meng-Chuan Huang1, Chih-Cheng Hsu, Huan-Sen Wang, Shyi-Jang Shin.
Abstract
OBJECTIVE: In this randomized controlled trial we evaluated the effect of registered dietitian-led management of diabetes on glycemic control and macronutrient intake in type 2 diabetic patients in primary care clinics in Taiwan and studied the association between changes in macronutrient intake and glycemic measures. RESEARCH DESIGN AND METHODS: We recruited 154 adult patients with type 2 diabetes and randomly assigned them to a routine care control group (n = 79) or a registered dietitian-led intervention group (n = 75) who received on-site diabetic self-management education every 3 months over 12 months.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19910499 PMCID: PMC2809255 DOI: 10.2337/dc09-1092
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 19.112
Baseline characteristics and changes of clinical parameters in type 2 diabetic patients after receiving a 12-month intervention or usual care (control)
| Baseline | Changes from baseline to 12 months | |||||
|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | |||
| 75 | 79 | 75 | 79 | |||
| Baseline characteristics | ||||||
| Age (years) | 56.6 ± 8.0 | 56.9 ± 7.5 | 0.802 | — | — | — |
| Diabetes duration (years) | 4.8 ± 4.4 | 4.8 ± 4.5 | 0.996 | — | — | — |
| Male sex (%) | 29 (38.7) | 38 (48.1) | 0.238 | — | — | — |
| Education | ||||||
| <6 years primary school | 45 (60.0) | 59 (74.7) | 0.052 | — | — | — |
| >6 years primary school | 30 (40.0) | 20 (25.3) | — | — | — | |
| Clinical measurements | ||||||
| Height (cm) | 159.1 ± 8.3 | 161.1 ± 8.2 | 0.141 | −0.1 ± 1.2 | −0.1 ± 1.0 | 0.872 |
| BMI (kg/m2) | 25.7 ± 3.2 | 27.0 ± 4.7 | 0.044 | 0.1 ± 1.2 | 0.2 ± 1.5 | 0.733 |
| Systolic blood pressure (mmHg) | 131.8 ± 19.8 | 134.9 ± 17.4 | 0.304 | −0.7 ± 15.8 | 6.0 ± 18.9 | 0.019 |
| Diastolic blood pressure (mmHg) | 79.7 ± 10.5 | 84.2 ± 10.3 | 0.008 | 0.0 ± 11.0 | 0.6 ± 10.9 | 0.736 |
| Glucose (mg/dl) | 147.4 ± 49.6 | 159.7 ± 53.4 | 0.141 | −6.8 ± 50.1 | 12.7 ± 56.9 | 0.026 |
| A1C (%) | 8.0 ± 1.5 | 8.4 ± 1.8 | 0.212 | −0.5 ± 1.1 | −0.1 ± 1.5 | 0.101 |
| Triglyceride (mg/dl) | 145.4 ± 90.2 | 164.6 ± 122.9 | 0.272 | −3.8 ± 69.2 | −0.3 ± 110.8 | 0.818 |
| Total cholesterol (mg/dl) | 183.0 ± 37.9 | 187.3 ± 38.4 | 0.488 | −5.1 ± 39.3 | 0.3 ± 43.7 | 0.424 |
| HDL cholesterol (mg/dl) | 50.1 ± 12.2 | 48.7 ± 11.1 | 0.471 | −0.1 ± 11.2 | −0.6 ± 8.7 | 0.743 |
| LDL cholesterol (mg/dl) | 117.8 ± 33.4 | 118.5 ± 32.5 | 0.898 | −6.0 ± 35.9 | 0.1 ± 36.3 | 0.297 |
| GPT (units/l) | 35.3 ± 26.5 | 40.1 ± 35.9 | 0.350 | 2.9 ± 44.6 | −0.3 ± 25.0 | 0.582 |
| Creatinine (mg/dl) | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.631 | 0.0 ± 0.4 | 0.0 ± 0.2 | 0.765 |
| Uric acid (mg/dl) | 5.5 ± 1.6 | 5.6 ± 1.9 | 0.670 | 0.5 ± 1.3 | 0.2 ± 1.7 | 0.235 |
| hs-CRP (mg/dl) | 0.4 ± 1.3 | 0.3 ± 0.3 | 0.693 | −0.1 ± 1.5 | −0.1 ± 0.4 | 0.790 |
Data are means + SD or n (%). A t test or χ2 test was used to test differences between the intervention and control subjects at baseline. A t test was also used to determine the changes in clinical parameters between the two groups after a 1-year intervention. P < 0.05 is considered significantly different. GPT, glutamic pyruvic transanimase; hs-CRP, high-sensitivity C-reactive protein.
Baseline characteristics and changes of clinical parameters and medication in type 2 diabetic patients with baseline A1C ≥7% after receiving a 12-month intervention or usual care (control)
| Baseline | Changes from baseline to 12 months | |||||
|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | |||
| 56 | 60 | 56 | 60 | |||
| Baseline characteristics | ||||||
| Age (years) | 55.8 ± 8.2 | 57.4 ± 7.5 | 0.286 | — | — | — |
| Diabetes duration (years) | 5.2 ± 4.5 | 5.5 ± 4.7 | 0.665 | — | — | — |
| Male sex (%) | 23 (41.1) | 31 (51.7) | 0.253 | — | — | — |
| Education | ||||||
| <6 year primary school | 34 (60.7) | 45 (75.0) | 0.099 | — | — | — |
| >6 year primary school | 22 (39.3) | 15 (25.0) | — | — | — | |
| Medication use | ||||||
| Glucose-lowering treatment | ||||||
| Sulfonylurea | 54 (96.4) | 57 (95.0) | 1.000 | — | — | — |
| Biguanide | 45 (80.4) | 50 (83.3) | 0.677 | — | — | — |
| Thiazolidinedione | 7 (12.5) | 14 (23.3) | 0.130 | — | — | — |
| Other oral hypoglycemia agent | 0 (0.0) | 2 (3.3) | 0.496 | — | — | — |
| Lipid-lowing treatment | ||||||
| Gemfibrozil | 2 (3.6) | 0 (0.0) | 0.231 | — | — | — |
| Statins | 21 (37.5) | 13 (21.7) | 0.061 | — | — | — |
| Fibrate | 0 (0.0) | 1 (1.7) | 1.000 | — | — | — |
| Antihypertensive treatment | ||||||
| Diuretics | 1 (1.8) | 2 (3.3) | 1.000 | — | — | — |
| β-Blocker | 0 (0.0) | 2 (3.3) | 0.496 | — | — | — |
| α-Blocker | 1 (1.8) | 1 (1.7) | 1.000 | — | — | — |
| Calcium-channel blocker | 17 (30.4) | 20 (33.3) | 0.731 | — | — | — |
| ACE inhibitor | 7 (12.5) | 9 (15.0) | 0.696 | — | — | — |
| Angiotensin receptor blocker | 4 (7.1) | 7 (11.7) | 0.531 | — | — | — |
| Aspirins | 4 (7.1) | 8 (13.3) | 0.365 | — | — | — |
| Clinical measurements | ||||||
| Height (cm) | 159.3 ± 8.2 | 161.2 ± 8.4 | 0.206 | −0.1 ± 1.3 | −0.2 ± 1.0 | 0.769 |
| BMI (kg/m2) | 25.7 ± 3.2 | 26.8 ± 4.2 | 0.093 | 0.2 ± 1.3 | 0.2 ± 1.3 | 0.953 |
| Systolic blood pressure (mmHg) | 132.4 ± 20.9 | 134.3 ± 18.9 | 0.627 | 0.5 ± 16.8 | 8.6 ± 17.4 | 0.012 |
| Diastolic blood pressure (mmHg) | 80.1 ± 10.5 | 84.2 ± 10.4 | 0.038 | 0.6 ± 11.5 | 0.4 ± 10.0 | 0.945 |
| Glucose (mg/dl) | 160.8 ± 49.6 | 173.7 ± 52.7 | 0.178 | −13.4 ± 55.2 | 16.9 ± 63.6 | 0.007 |
| A1C (%) | 8.6 ± 1.2 | 9.0 ± 1.5 | 0.087 | −0.7 ± 1.1 | −0.2 ± 1.7 | 0.034 |
| Triglyceride (mg/dl) | 157.9 ± 97.7 | 161.8 ± 126.2 | 0.856 | −9.7 ± 67.9 | 3.6 ± 111.8 | 0.445 |
| Total cholesterol (mg/dl) | 183.8 ± 38.1 | 191.5 ± 39.4 | 0.290 | −5.8 ± 38.9 | −0.3 ± 44.7 | 0.485 |
| HDL cholesterol (mg/dl) | 48.4 ± 10.7 | 47.8 ± 11.2 | 0.778 | 0.6 ± 10.6 | 0.0 ± 8.1 | 0.734 |
| LDL cholesterol (mg/dl) | 119.5 ± 32.0 | 123.5 ± 32.3 | 0.500 | −7.3 ± 35.1 | −1.9 ± 37.2 | 0.430 |
| GPT (units/l) | 37.6 ± 27.5 | 38.8 ± 34.5 | 0.840 | −2.8 ± 18.1 | 0.0 ± 22.9 | 0.468 |
| Creatinine(mg/dl) | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.662 | 0.0 ± 0.4 | 0.0 ± 0.2 | 0.883 |
| Uric acid(mg/dl) | 5.5 ± 1.6 | 5.6 ± 2.1 | 0.819 | 0.5 ± 1.3 | 0.3 ± 1.8 | 0.451 |
| hs-CRP (mg/dl) | 0.5 ± 1.5 | 0.3 ± 0.3 | 0.540 | −0.1 ± 1.8 | −0.1 ± 0.3 | 0.908 |
Data are means ± SD or n (%). A t test or χ2 test (Fisher test was used as n < 5) was used to test differences between the intervention and control subjects at baseline. A t test was also used to determine the changes in clinical parameters between the two groups after a 1-year intervention. P < 0.05 is considered significantly different. GPT, glutamic pyruvic transanimase; hs-CRP, high-sensitivity C-reactive protein.
Changes in nutrient intakes in type 2 diabetic patients with baseline A1C ≥7% after receiving a 12-month intervention or usual care (control)
| Nutrient intakes | Baseline | Changes from baseline to 12 months | ||||
|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | |||
| 56 | 54 | 56 | 54 | |||
| Energy (kcal/day) | 1,899.0 ± 399.8 | 1,877.5 ± 405.3 | 0.778 | −229.06 ± 309.16 | 56.10 ± 309.41 | <0.001 |
| Carbohydrates | ||||||
| Energy % | 54.4 ± 7.9 | 54.4 ± 8.5 | 0.999 | 0.01 ± 9.29 | −1.01 ± 7.64 | 0.530 |
| g/day | 256.4 ± 58.8 | 245.0 ± 45.1 | 0.250 | −31.24 ± 61.53 | 7.15 ± 54.09 | 0.001 |
| Protein | ||||||
| Energy % | 14.9 ± 2.8 | 14.8 ± 3.5 | 0.786 | −0.52 ± 3.60 | 0.12 ± 3.50 | 0.345 |
| g/day | 70.4 ± 18.3 | 68.4 ± 24.6 | 0.622 | −10.91 ± 18.85 | 2.94 ± 18.60 | <0.001 |
| Fat | ||||||
| Energy % | 30.6 ± 6.7 | 30.8 ± 6.9 | 0.899 | 0.51 ± 7.92 | 0.89 ± 7.20 | 0.793 |
| g/day | 64.8 ± 21.0 | 63.3 ± 22.4 | 0.712 | −7.74 ± 18.36 | 3.84 ± 19.99 | 0.002 |
| Monounsaturates (%) | 9.7 ± 3.0 | 10.0 ± 3.7 | 0.686 | 0.61 ± 3.91 | 1.00 ± 3.70 | 0.596 |
| Polyunsaturates (%) | 10.9 ± 3.0 | 11.0 ± 3.7 | 0.852 | −0.05 ± 4.47 | −0.65 ± 4.83 | 0.500 |
| Saturates (%) | 8.7 ± 3.1 | 7.8 ± 2.9 | 0.141 | −0.98 ± 3.40 | 0.60 ± 2.93 | 0.010 |
| Cholesterol (mg/day) | 237.3 ± 176.7 | 234.6 ± 178.9 | 0.935 | −3.59 ± 200.15 | 14.97 ± 223.45 | 0.647 |
Data are means ± SD. A t test was used to test differences between the intervention and control subjects at baseline. A t test was also used to determine the changes in nutrient intakes between the two groups after a 1-year intervention. There were four subjects with missing dietary data at 1-year follow-up in the control group (n = 54). P < 0.05 is considered significantly different.
Univariate and multivariate regression analysis of factors associated with changes of A1C in intervention subjects with baseline A1C ≥7% after receiving a 12-month intervention
| Simple linear regression | Multiple linear regression | |||
|---|---|---|---|---|
| β (SEM) | β (SEM) | |||
| Age (years) | −0.031 (0.018) | 0.096 | −0.013 (0.12) | 0.304 |
| Sex | −0.252 (0.304) | 0.411 | −0.367 (0.205) | 0.080 |
| Duration of diabetes (years) | −0.016 (0.033) | 0.641 | 0.027 (0.023) | 0.232 |
| Baseline BMI | 0.104 (0.045) | 0.026 | 0.042 (0.032) | 0.200 |
| Baseline A1C (%) | −0.606 (0.093) | <0.001 | −0.454 (0.084) | <0.001 |
| Change in energy intake (100 kcal/day) | 0.200 (0.041) | <0.001 | 0.045 (0.043) | 0.303 |
| Change in carbohydrate intake (15 g/day) | 0.167 (0.029) | <0.001 | 0.100 (0.033) | 0.004 |
| Change in fat intake (15 g/day) | 0.002 (0.124) | 0.988 | — | — |
| Change in protein intake (15 g/day) | 0.188 (0.118) | 0.117 | — | — |
n = 56.